This is a demo store. No orders will be fulfilled.

Risankizumab (anti-IL-23) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL23A, >95%, high purity, Human IgG1, INHIBITOR of Interleukin-23 inhibitor, INHIBITOR of Interleukin-23 inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Cynomolgus monkey,Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab169268
Grouped product items
SKU Size
Availability
Price Qty
Ab169268-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$139.90
Ab169268-1mg
1mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$657.90
Ab169268-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$1,407.90
Ab169268-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,457.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Risankizumab (anti-IL-23) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL23A, >95%, high purity, Human IgG1, INHIBITOR of Interleukin-23 inhibitor
Synonyms Recombinant Risankizumab Antibody | Risankizumab | Risankizumab rzaa | BI 655066 | Risankizumab (anti-IL-23) | Anti-IL-23a Reference Antibody (risankizumab) | IL 23 A antibody | IL 23 antibody | IL 23 subunit alpha antibody | IL 23A antibody | IL 23p19 an
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity IL23A
Application ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of Interleukin-23 inhibitor
Product Description

Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg 

Product Properties

Antibody Type Primary antibody
Clonality Recombinant
Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 26.1 kDa (Light Chain) & 51.0 kDa (Heavy Chain), under reducing conditions; 166.7 kDa, under non-reducing conditions.
Purification Method Protein A purified
Purity >95%
Source CHO supernatant
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 1612838-76-2

Associated Targets(Human)

IL23A Tclin Interleukin-23 subunit alpha (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Images

Risankizumab (anti-IL-23) (Ab169268) - SEC
The purity of Risankizumab (anti-IL-23) (Ab169268) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot Number Certificate Type Date Item
ZJ23F0901031 Certificate of Analysis Sep 14, 2023 Ab169268
ZJ23F0901029 Certificate of Analysis Sep 14, 2023 Ab169268

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.